Papadopoulos will report directly to Emergex's CEO Professor Thomas Rademacher.
In his new role Papadopoulos will use his extensive medical, regulatory and clinical development expertise to provide leadership and direction on the development of Emergex's growing pipeline of vaccines.
Papadopoulos joins Emergex from Sanofi, the global pharmaceutical company, where he was most recently Associate vice president, senior director and Clinical Franchise Leader of Global Clinical Sciences since 2015. During his time at Sanofi Dr. Papadopoulos played a critical role in the development of Dengvaxia, the first vaccine approved for Dengue fever.
Prior to joining Sanofi, Dr. Papadopoulos worked at Novartis as Medical Affairs director and Senior Global Clinical Research Physician as well as Lead Head of CLS and Senior director of Clinical Development. During his time at Novartis, he contributed to the successful development and approval of the breakthrough Bexsero Meningitis B vaccine.
Papadopoulos originally trained as a general practitioner in Greece and specialized as a clinical bio-pathology consultant.
Emergex Vaccines Holding, a UK-based biotechnology company headquartered in Oxford, is developing a new approach to vaccine development in order to address some of the world's most immediate health threats including Flaviviruses, such as Dengue Fever and Zika as well as Filoviruses, such as Ebola and Marburg viruses, and seasonal and pandemic influenza.
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
RedHill Biopharma secures USPTO Patent for Talicia, extending protection through 2034
Micron Biomedical names new scientific advisor to CEO
Quanterix partners with leading health networks for Alzheimer's diagnosis advancements
Precision BioSciences reports FDA pre-IND feedback for PBGENE-HBV
VBI to sell manufacturing capabilities and enter new license agreement with Brii Biosciences
Ondine Biomedical's Steriwave shows promise in nasal pathogen reduction
BioSenic expands patent coverage for ATO therapeutic platform
PacBio unveils Nanobind PanDNA kit for enhanced DNA extraction solutions
Sequentify receives funding from Israel Innovation Authority
INOVIO plans BLA submission for INO-3107 as RRP treatment
ImmunityBio secures USD320m investment from Oberland Capital
Poolbeg Pharma prioritises promising RSV drug candidates identified through AI-led analysis
GHIT fund invests JPY500m in antimalarial drug clinical trial